Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?
While Viva Biotech Holdings ( HKG:1873 ) might not be the most widely known stock at the moment, it saw a double-digit...
Hong Kong (HSI) Clinical Research and Equipment Industry Analysis
UpdatedAug 09, 2022
DataAggregated Company Financials
Companies6
- 7D3.8%
- 3M40.2%
- 1Y-41.7%
- YTD-16.7%
Over the last 7 days, the Clinical Research and Equipment industry has remained flat, although notably Genscript Biotech gained 7.9%. As for the longer term, the industry has declined 39% in the last year. Earnings are forecast to grow by 29% annually.
Industry Valuation and Performance
Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 09 Aug 2022 | HK$386.6b | HK$22.3b | HK$2.0b | 12.1x | 189.7x | 17.4x |
| Thu, 07 Jul 2022 | HK$433.0b | HK$22.4b | HK$2.1b | 15.1x | 209.4x | 19.4x |
| Sat, 04 Jun 2022 | HK$299.3b | HK$22.5b | HK$2.1b | 13.1x | 142x | 13.3x |
| Mon, 02 May 2022 | HK$312.2b | HK$22.7b | HK$2.2b | 14x | 145.1x | 13.8x |
| Wed, 30 Mar 2022 | HK$351.9b | HK$22.5b | HK$2.3b | 20.3x | 154.9x | 15.6x |
| Fri, 25 Feb 2022 | HK$337.4b | HK$18.8b | HK$2.8b | 20.3x | 118.9x | 18x |
| Sun, 23 Jan 2022 | HK$461.8b | HK$18.7b | HK$2.8b | 31.4x | 164x | 24.7x |
| Tue, 21 Dec 2021 | HK$455.9b | HK$18.6b | HK$2.8b | 32.6x | 163x | 24.4x |
| Thu, 18 Nov 2021 | HK$581.2b | HK$18.6b | HK$2.8b | 35.5x | 209x | 31.3x |
| Sat, 16 Oct 2021 | HK$560.2b | HK$18.5b | HK$2.8b | 52.8x | 203.1x | 30.4x |
| Mon, 13 Sep 2021 | HK$594.7b | HK$18.4b | HK$2.7b | 51.4x | 216.7x | 32.3x |
| Wed, 11 Aug 2021 | HK$633.3b | HK$18.4b | HK$2.7b | 50.8x | 230.8x | 34.4x |
| Sun, 06 Jun 2021 | HK$611.0b | HK$15.7b | HK$1.4b | 58.3x | 422.9x | 39x |
| Wed, 10 Mar 2021 | HK$456.6b | HK$13.1b | HK$201.6m | 71.2x | 2265.3x | 34.8x |
| Tue, 01 Dec 2020 | HK$359.1b | HK$11.4b | HK$4.7m | 63.8x | 77189.9x | 31.6x |
| Fri, 04 Sep 2020 | HK$330.1b | HK$9.7b | -HK$169,775,475.51 | 84.1x | -1944.1x | 34.1x |
| Mon, 08 Jun 2020 | HK$213.6b | HK$9.2b | HK$329.6m | 95.9x | 647.9x | 23.1x |
| Sun, 01 Mar 2020 | HK$198.4b | HK$9.0b | HK$860.3m | 67.3x | 230.6x | 22.1x |
| Wed, 04 Dec 2019 | HK$167.4b | HK$8.2b | HK$916.5m | 58.6x | 182.6x | 20.5x |
| Sat, 07 Sep 2019 | HK$152.2b | HK$7.6b | HK$1.0b | 66x | 145.1x | 20x |
Price to Earnings Ratio
145.1x
Current Industry PE
- Investors are pessimistic on the Hong Kong Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 193x which is lower than its 3-year average PE of 6kx.
- The 3-year average PS ratio of 25.8x is higher than the industry's current PS ratio of 17.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have grown 25% per year over the last three years.
- Revenues for these companies have grown 43% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Hong Kong Clinical Research and Equipment compare with similar industries?
| HK Market | 0.21% | |
| Healthcare | 3.41% | |
| Life Sciences | 3.81% | |
| Clinical Research and Equipment | 3.81% | |
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$74.50 | 3.8% +HK$11.7b | -39.7% | PE80.7x | |
| 1548 Genscript Biotech | HK$28.55 | 3.6% +HK$2.1b | -19.6% | PS15x | |
| 1873 Viva Biotech Holdings | HK$2.12 | 4.4% +HK$171.8m | -70.8% | PE12.1x | |
| 1521 Frontage Holdings | HK$2.66 | 2.3% +HK$123.8m | -55.5% | PE37.9x | |
| 8225 China Health Group | HK$0.32 | 4.9% +HK$14.9m | -19.0% | PE9.3x |